Trial Profile
An Open-label, multicenter study to evaluate the safety and efficacy of Eltrombopag in patients with severe Immune Thrombocytopenic Purpura (ITP)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2017
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 20 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association